Research programme: G protein-coupled receptor modulators - Ogeda

Drug Profile

Research programme: G protein-coupled receptor modulators - Ogeda

Alternative Names: ESN-401; ESN-502; ESN-601; ESN-603; ESN-700

Latest Information Update: 21 Oct 2016

Price : $50

At a glance

  • Originator Euroscreen
  • Developer Euroscreen; Ogeda
  • Class Small molecules
  • Mechanism of Action G protein-coupled receptor modulators; G-protein coupled receptor 43 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Amyotrophic lateral sclerosis; Brain injuries; Parkinson's disease
  • Research Multiple sclerosis; Obesity; Rheumatoid arthritis; Type 2 diabetes mellitus; Ulcerative colitis
  • No development reported Inflammation

Most Recent Events

  • 19 Oct 2016 Euroscreen is now called Ogeda
  • 12 Sep 2016 CSN 502 is still in preclinical development for Parkinson's disease, Alzheimer's disease, Amyotrophic lateral sclerosis in Belgium (Euroscreen pipeline, September 2016)
  • 12 Sep 2016 Early research in Rheumatoid arthritis in Belgium (unspecified route) before September 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top